William Blair Initiates Coverage On Jack Henry & Associates with Outperform Rating

William Blair analyst Cristopher Kennedy initiates coverage on Jack Henry & Associates (NASDAQ:JKHY) with a Outperform rating.

byBenzinga Newsdesk

January 11, 2023

1 minute read

William Blair analyst Cristopher Kennedy initiates coverage on Jack Henry & Associates (NASDAQ:JKHY) with a Outperform rating.

Canaccord Genuity Maintains Buy on Evolent Health, Lowers Price Target to $48

By Benzinga Newsdesk

Today, 11:49 AM

Canaccord Genuity analyst Richard Close maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $55 to $48.

EVH

Broadway Issues $150M Of Preferred Stock To The U.S. Department Of The Treasury Under The Emergency Capital Investment Program

By Benzinga Newsdesk

Today, 11:49 AM

Broadway Issues $150 million of Preferred Stock to the U.S. Department of the Treasury Under the Emergency Capital Investment Program Broadway Financial Corporation ("Broadway", "we" or the

BYFC

ClearPoint Neuro Q1 EPS $(0.17) Beats $(0.20) Estimate, Sales $5.00M Beat $4.18M Estimate

By Michael Horton

Today, 11:49 AM

ClearPoint Neuro (NASDAQ:CLPT) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.20) by 15 percent. This is a 30.77 percent decrease over losses of $(0.13) per share from the

CLPT

Analyst Ratings

Piper Sandler Maintains Overweight Rating for Beauty Health: Here’s What You Need To Know

By Benzinga Insights

Today, 11:49 AM

Piper Sandler has decided to maintain its Overweight rating of Beauty Health (NASDAQ:SKIN) and lower its price target from $26.00 to $24.00. Shares of Beauty Health are trading down 0.76% over the last 24 hours, at $12.40 per share.

SKIN

William Blair Initiates Coverage On Jack Henry & Associates with Outperform Rating

Related Posts

Canaccord Genuity Maintains Buy on Evolent Health, Lowers Price Target to $48

Broadway Issues $150M Of Preferred Stock To The U.S. Department Of The Treasury Under The Emergency Capital Investment Program

ClearPoint Neuro Q1 EPS $(0.17) Beats $(0.20) Estimate, Sales $5.00M Beat $4.18M Estimate

Piper Sandler Maintains Overweight Rating for Beauty Health: Here’s What You Need To Know